The term cardiomyopathy constitutes a group of disease in which the dominant feature is involvement of heart muscle itself.
For more than 30 years the term cardiomyopathy has been used to describe disorders of the heart with particular morphological and physiological characteristics. 3, 6, 7 A variety of schemes has been proposed for classifying the cardiomyopathies, such as-1. Functional classification 2. Etiologic classification 3. Endomyocardial biopsy/ histology 4. International classification of diseases (ICD-9/10) 5 . Therapeutic classification
Gene based classification
Since the first WHO official classification 1 1tremendous progress has been made. 2 Novel entities have been discovered requiring an update of the WHO classification in 1995 3 , the etiology of many forms has been clarified .
Among the above classifications no single classification of cardiomyopathies is generally accepted within the biomedical community.
In 2006,the AHA task published a new definition and classification of cardiomyopathy-called AHA 2006 scientific statement . 4 The working geoup of myocardial and pericardial disease of the Europian Society of Cardiology recently published a statement -Position statement different from the 2006,AHA scientific statement. 5
Functional classification
Functional classification ( Table-1 Dilatation -is dominated by LV cavity enlargement and systolic failure Hypertrophy-is dominated by LV wall thickening and diastolic failure.
Restriction-inadequate compliance causing restriction of diastolic filling.
The value of this functional classification is thatvirtually all cardiomyopathies are readily placed or categorized in one of the three categories and the therapeutic approaches to each category are dominantly different.
This Functional classification has some short comings also- Despite this short comings Functional classification remains the most popular among the clinicians because it is based on easily understood physiologically and is relevant to therapy. US National Centre Of Health Statistics modified the ICD-9 code to allow coding of medical records.
But it is impossible to remember the long listed code numbers, so difficult to use by the physician and also the scientist. 
Therapeutic classification
Therapeutic classification ( Table-6 ): based on specific therapies borrows heavily from the functional and the etiologic classification of cardiomyopathy.
Nevertheless this classification also some shortcomings and so difficult to use.
1. More than one class of therapy is appropriate for a disease.
2. Therapeutic preferences are subject to variances in opinion and to change with new approaches.
3. When new therapy introduced, the existing classification become obsolete.
4.
Commonly used therapies such as-inotropic agents and cardiac transplantation therapy are not included in this classification. The concept of Specific cardiomyopathies was widened too much so as to include myocardial diseases due to valvular disease, systemic hypertension; coronary artery disease and pericardial disease were also included as Specific cardiomyopathies.
-Myocarditis also included in these Specific cardiomyopathies as inflammatory cardiomyopathy.
Although the 1995 classification made significant contribution (acknowledging new entities, unifying terminology including myocarditis) nonetheless it introduced ambiguities by classifying the ischemic and overload disorders among the cadiomyopathies. In particular the popular hypertrophic -dilatedrestrictive cardiomyopathies classification has major limitations by virtue of mixing anatomic designations (i.e.hypertrophic and dilated) with functional one (i.e. restrictive). Consequently confusion arises when the same disease could appear in or even three categories and some diseases do not have uniformly static expression and may evolve from one category to another during their clinical course. For example HCM, Amyloid and other infiltrative myocardial conditions may progress from a non dilated state with ventricular stiffness to a dilated form with systolic dysfunction and heart failure.
Etiologic classifications of cardimyopathies are also problematic given that the diseases with the same / similar phenotypes can harbor diverse etiologies and mechanisms. For example-DCM may genetic, infective, autoimmune and toxic causes (and in some cases are still designated as idiopathic) all leading, however to the final common pathway of ventricular dilatation with systolic dysfunction.
However with the identification of new diseases over the past decades and recent advances in cardiovascular diagnosis and knowledge regarding etiology , some diseases definitions have become outdated and past classification rendered essentially obsolete. The great advances in the field of cardiomyopathies came from the rapid revolution of molecular biology in cardiology made fundamental step forward in understanding the genetics of cardiomyopathies. In particular ion channelopathies have emerge d as condition predisposing to potentially lethal ventricular tachyarrhythmia and by mutations in proteins leading to dysfunctional Sodium ,Potassium , calcium and other ion channels.
In 2006, the AHA Task force incorporated the above ideas in a scientific statement -called AHA 2006 scientific statement ,advancing a new definition and classifications.
The AHA task force proposed a 'beyond of phenotype' classification of cardiomyopathies that groups under such a designation all myocardial diseases whose common denominator is a genetic defect, consisting of mutants gene encoding sarcomeric, cytoskeleton ,desmosomal or ion channel proteins.
Accordingly the AHA task force proposed following definition of cardiomyopathy-Cardiomyopathies are a heterogeneous group of diseases of the myocardium associated with mechanical and/or electrical dysfunction that usually (but not invariably) exhibit inappropriate ventricular hypertrophy and dilatation and are due to a variety of causes that frequently are genetic.
In AHA scientific statement, the original pmimary and secondary forms of cardiomyopathy was reintroduced but with slight modification of definition .
Primary cardiomyopathies are those solely or predominantly confined to the heart muscle .
Primary cardiomyopathies have been divided into three main categories ( 
ESC position statement
The rationale for a new classification: With the advancement of molecular biology, Expert committee of AHA proposed new definition and classification of cardiomyopathy.Primary and secondary cardimyopathies as describes in AHA proposed new definition and classification, the challenges of distinguishing primary and secondary cardiomyopathies is still remains controversial because-many of the diseases classed as proposed primary cardiomyopathies can be associated with major extra-cardiac manifestations and conversely pathology in many of the diseases classed as secondary cardiomyopathies can predominantly (or exclusively) involve the heart.
As many cardiomyopathies are caused by mutations in genes that encode various cardiac proteins, an alternative approach is to classify cardiomyopathies according to the causative genetic defect.
However in clinical practice the pathway from diagnosis to treatment rarely begins with the identification of an underlying genetic mutation; more usually patients present with symptoms or are incidentally found to have clinical signs or abnormal screening tests. Even when the genetic defect is known in a family, the identification of clinically relevant disease in gene carriers still requires the demonstration of a morphological phenotype.
Thus the clinically oriented classification system in which heart muscle disorders are grouped according to ventricular morphology and function remains the most useful method for diagnosing and managing patients and families with heart muscle disease.
Considering the above mentioned situations, In 2007 ESC working group on myocardial and pericardial diseases published a new classification of cardiomyopathies, known as 2007 ESC. position statement. . (Table no: 
)
In this statement cardiomyopathy is defined as-A myocardial disorder in which the heart muscle is structurally and functionally abnormal in the absence of coronary artery disease, hypertension, valvular heart disease and congenital heart disease sufficient to cause the observed myocardial abnormality.
In this statement Cardiomyopathies are grouped into 5 specific morphological and functional phenotypes.
Each phenotype is again sub classified into two forms-Familial and Non-familial. Each Familial is again subdivided into two forms-Familial due to unknown gene and Familial due to known gene. Familial-clinically defined by the occurrence in more than one family member of either the same disorder or phenotype. That is (or could be) caused by the same genetic mutation and not to acquired cardiac or systemic diseases in which the clinical phenotype is influenced by genetic polymorphism.
While accepting and reinforcing the idea advanced by AHA statement to divide cardiomyopathies into familial/ genetic and non-familial / nongenetic the traditional division of primary and secondary cardiomyopathies have abolished in the position statement.
Most familial cardiomyopathies are monogenic disorder i.e. The gene defect is sufficient by itself to cause the trait. Familial category can be subsequently transmitted to their offspring.
Non-familial-clinically defined by the presence of a cardiomyopathy in the index patient and the absence of disease in the other family members.
Each Non familial is again subdivided into two forms-Non familial due to unknown gene and Non familial due to known gene .
Moreover ,the concept of pure electrical dysfunction was denied ,thus ruling out ion channel and conduction system disease from this classification, because recent studies suggest that genes encoding ion channels may be implicated in subgroups of patients with DCM ,conduction disorders and arrhythmias do not provide an argument for the redesignation of channelopathies as cardiomyopathies at the present time. 
This classification-
• Based on specific morphological and functional phenotypes rather than putative pathophysiological mechanism.
• Classified into familial and non familial forms so as to raise the awareness of genetic determinants of cardiomyopathies and to orient diagnostic test (including the search for specific mutations when appropriate)
• Again discard the term primary and secondary form of cardiomtopathies.
• Reintroduction of the unclassified variety of cardiomyopathy.
Limitations of 2007 ESC. position statement.
1. There are circumstances in which this classification system fails to describe fully the complexity the of some disease phenotypes such as-• Occurrence of different cardiomyopathies caused by the same genetic mutations (in related and unrelated individuals).
• The evolution one disease phenotype into another overtime. 2. Another limitation of the proposed classification is the problem of the mixed phenotype ,for example -in patient with dilated and hypertrophied ventricles 3. This proposed classification does not provide guidance on the diagnostic algorhythm that should be followed whenever a cardiomyopathy is diagnosed.
Conclusion:
Indeed no past or present classification of cardiomyopathies is likely to satisfy the purposes of all interested parties. The aim of this classification is to help clinicians look beyond generic diagnostic labels in order to reach more specific diagnosis that may be useful for tailored clinical management of patients and their families.
2007 ESC position statement working group hope that subsequent revisions of the classification based on emerging data will resolve remaining shortcomings and ambiguities.
